Elevance Health Inc.

ELV ·Financial, Insurance - Health, United States

Elevance Health (ELV)

Overview

Elevance Health, Inc. is one of the largest health benefits (health insurance) companies in the United States, headquartered in Indianapolis, Indiana. Formerly known as Anthem, Inc., the company rebranded to Elevance Health in June 2022 to reflect a broader ambition to move beyond traditional insurance into health services. Elevance is the largest for-profit licensee of the Blue Cross Blue Shield Association, operating Blue-branded health plans across 14 states, and is frequently cited among the largest healthcare companies in the world by revenue. The company generated roughly $199 billion in revenue in fiscal 2025 and employs around 97,000–104,000 people, serving tens of millions of medical members plus tens of millions more through its pharmacy and services businesses.

What They Do & How They Make Money

Elevance's core business is health insurance: it collects premiums from employers, individuals, and government programs (Medicare and Medicaid) in exchange for managing members' healthcare costs and access to provider networks. The bulk of revenue comes from "risk-based" premiums, where Elevance assumes the financial risk of members' medical costs and profits on the spread between premiums collected and claims paid plus administrative costs (the industry's "medical loss ratio" dynamic). It also earns fee-based administrative revenue from self-funded employer plans that only want Elevance to administer claims and provider networks without taking on insurance risk. Beyond insurance, Elevance has been diversifying into a broader "health services" model under its Carelon brand — pharmacy benefit management (CarelonRx), behavioral health, care/utilization management, and healthcare-enablement services sold both to its own health plan members and to external clients (including other insurers). This diversification is intended to capture more of the healthcare dollar beyond the insurance premium itself and reduce reliance on medical-loss-ratio-capped insurance margins.

Business Segments

Per its 10-K, Elevance reports results across the following segments/divisions:

Health Benefits — the core insurance business, covering Commercial (employer group risk-based and fee-based, and individual), Medicare (including Medicare Advantage), Medicaid, and BlueCard (servicing members traveling or living outside their home Blue plan's area) and FEP (Federal Employee Program) members. This is by far the largest segment, generating roughly $42–43 billion in quarterly revenue (well over 80% of total company revenue), though it typically runs thinner margins due to regulatory medical-loss-ratio requirements.
Carelon (combining CarelonRx and Carelon Services) — the health-services arm. CarelonRx provides pharmacy benefit management: home delivery and specialty pharmacy, claims adjudication, formulary management, and rebate negotiation. Carelon Services provides behavioral health management, care/utilization management, palliative and complex care, and data/analytics services, sold to Elevance's own plans as well as external health-plan and provider clients. Combined, Carelon generates roughly $19 billion in quarterly revenue and has been the company's fastest-growing and highest-margin segment, contributing an outsized share of operating gain relative to its revenue.
Corporate & Other — investment income, corporate overhead, and other non-segment items.

Competitors

Elevance competes across several distinct lines of business:

National managed-care insurers: UnitedHealth Group (and its UnitedHealthcare and Optum units), CVS Health (Aetna), Cigna, Humana, and Centene Corporation.
Medicaid/government-focused insurers: Centene, Molina Healthcare, and UnitedHealthcare Community Plan.
Other Blue Cross Blue Shield licensees: independently operated, not-for-profit Blue plans in states outside Elevance's footprint (e.g., Health Care Service Corporation), which are technically fellow BCBSA members but compete for national/multi-state employer accounts.
Pharmacy benefit management (CarelonRx): CVS Caremark, Express Scripts (Cigna/Evernorth), and OptumRx (UnitedHealth Group) — the three PBMs that, together with CarelonRx, dominate the U.S. PBM market.
Regional and specialty plans in Medicare Advantage (e.g., Humana) and behavioral/complex-care services (e.g., Optum Behavioral Health).

Competitive Position

Elevance's principal moat is its exclusive Blue Cross Blue Shield branding and provider-network relationships across its 14-state footprint, which gives it strong brand recognition and negotiating leverage with hospitals and physicians in those markets — advantages that are difficult and slow for a new entrant to replicate. Its scale (tens of millions of members) gives it purchasing power in drug procurement and provider contracting, and its multi-brand strategy (Anthem, Wellpoint, Amerigroup, Carelon) lets it address commercial, Medicare, and Medicaid customers separately. The Carelon diversification strategy is a deliberate attempt to mimic UnitedHealth's highly profitable Optum playbook — extracting more margin from services (PBM, care management, data analytics) that are not constrained by medical-loss-ratio caps the way core insurance is, and cross-selling those services to external clients.

Key risks and threats include: regulatory and political pressure on Medicare Advantage reimbursement rates and risk-adjustment practices; state and federal Medicaid redetermination cycles, which caused membership volatility as pandemic-era continuous-coverage rules unwound in 2023–2024; rising medical cost trends (utilization, specialty drug and GLP-1 costs) that can outpace premium pricing; PBM industry scrutiny and potential regulatory reform (transparency mandates, spread-pricing bans); intensifying competition from UnitedHealth's much larger Optum platform; litigation and reputational risk around claims-denial and "ghost network" practices; and cybersecurity risk given the sensitivity of health data the company holds. Elevance's success in shifting its earnings mix toward Carelon, while defending its core Blue-branded insurance franchise from both national competitors and Medicaid-focused specialists, is central to its long-term competitive trajectory.